AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

MEDICA GROUP PLC

AGM Information Jun 27, 2022

4972_dva_2022-06-27_5798d56e-6468-4a4b-9c4e-551656788d57.html

AGM Information

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 3317Q

Medica Group PLC

27 June 2022

27 June 2022

Medica Group Plc

Result of Annual General Meeting

Medica Group PLC (LSE:MGP, "Medica" or the "Company"), the UK and Ireland market leader in the provision of teleradiology services, announces that, at its Annual General Meeting held at 11.00am today, all resolutions put to the meeting were duly passed.

Details of the voting are as follows:

Resolution

For/

Discretion

(Number of

votes)

%

For/

Discretion

Against

(Number of votes)

%

Against

Total

votes

Withheld

(Number of votes)

Ordinary Business

1.  

To receive and adopt the annual report, accounts and the auditor's report

100,735,575

100.00

0

0.00

100,735,575

1,173,666

2.  

To approve the Directors' Remuneration Report (excluding Remuneration Policy)

100,703,036

99.72

279,222

0.28

100,982,258

926,983

3.  

To approve the amendments to the rules of the Performance Share Plan

100,165,535

99.19

814,918

0.81

100,980,453

928,788

4.  

To declare a final dividend

100,985,486

100.00

0

0.00

100,985,486

923,755

5.  

To re-appoint Grant Thornton UK LLP as auditors

100,731,909

99.995

4,728

0.005

100,736,637

1,172,604

6.  

To authorise the directors to determine the remuneration of the auditors

100,981,201

100.00

0

0.00

100,981,201

928,040

7.  

To re-elect Roy Davis as a Director

101,032,592

99.21

807,948

0.79

101,840,540

68,701

8.  

To re-elect Joanne Easton as a Director

101,516,659

99.67

340,582

0.33

101,857,241

52,000

9.  

To re-elect Dr Junaid Bajwa as a Director

99,013,524

97.97

2,048,111

2.03

101,061,635

847,606

10.           

To re-elect Stuart Quin as a Director

101,834,429

99.98

20,355

0.02

101,854,784

54,457

11.           

To re-elect Richard Jones as a Director

101,602,107

99.998

2,028

0.002

101,604,135

305,106

12.           

To elect Barbara Moorhouse as a Director

101,850,479

100.00

0

0.00

101,850,479

58,762

Special Business

13.           

General authority to allot shares pursuant to Section 551 Companies Act 2006

100,912,668

99.93

68,956

0.07

100,981,624

927,617

14.           

General authority to allot equity securities pursuant to Section 570 Companies Act 2006

94,241,011

93.32

6,742,613

6.68

100,983,624

925,617

15.           

General authority to allot equity securities pursuant to Section 570 Companies Act 2006 for the purpose of financing an acquisition or other capital investment

94,240,212

93.32

6,742,717

6.68

100,982,929

926,312

16.           

Authority to make market purchases of up to 12,242,883 shares

100,680,388

99.75

253,649

0.25

100,934,037

975,204

17.          

To authorise the general meeting to be held on 14 clear days' notice

100,117,101

99.14

867,690

0.86

100,984,791

924,450

For further information, please contact:

Medica Group Plc:

Stuart Quin, Chief Executive Officer

Richard Jones, Chief Financial Officer
+44 (0)33 33 111 222
FTI Consulting

Victoria Foster Mitchell

Sam Purewal
+44 (0)20 3727 1000
Liberum (Joint Broker)

Phil Walker

Richard Lindley
+44 (0)20 3100 2000
Numis (Joint Broker)

Freddie Barnfield

Duncan Monteith

Euan Brown
+44 (0)20 7260 1000

About Medica Group PLC

Medica is the market leader in the UK and Ireland for the provision of teleradiology services, providing outsourced interpretation and reporting of MRI (magnetic resonance imaging), CT (computerised tomography), ultrasound and plain film (x-ray) images. Medica also offers diabetic retinopathy screening in Ireland.

Medica contracts with the largest pool of consultant radiologists in the UK and Ireland, performing remote access teleradiology across its customer base of more than 100 NHS Trusts in the UK, the Irish HSE, private hospital and insurance groups, as well as diagnostic imaging companies. This enables the Company to offer a fast, responsive service. In addition, Medica operates in Australia and New Zealand through MedX, a 50:50 Joint Venture with Integral Diagnostics Limited Pty.

The Company currently offers two primary services to hospital radiology departments:

·      NightHawk - urgent reporting service

·      Elective - includes routine cross-sectional reporting on MRI and CT scans, and routine plain film reporting on x-ray images.

These services are underpinned by Medica's bespoke, secure IT platform that provides market-leading linkage between a hospital's Radiology Information System (RIS) and consultant radiologists who contract with the Company. Direct RIS access ensures that where the wider patient medical history is available, it can be reviewed by the consultant as part of every report.

Through its subsidiary, RadMD, in the United States, Medica also provides pharmaceutical and biotech clients and contract research organisations (CROs) with high quality, complex imaging services for international clinical trials. RadMD has gained vast experience in the space, having contributed to over 500 international clinical trials, in all phases of clinical research from proof of concept to phase III and with expertise in oncology, as well as a wider range of therapeutic areas including medical devices, neurology and cardiovascular.

For more information please visit: www.medicagroupplc.com 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGEAAKXASKAEFA

Talk to a Data Expert

Have a question? We'll get back to you promptly.